Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec 16:45:110-112.
doi: 10.1016/j.jdcr.2023.11.029. eCollection 2024 Mar.

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib

Arianna Zhang  1   2 , Rebecca G Gaffney  2 , Joseph F Merola  3   4
Affiliations
Case Reports

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib

Arianna Zhang et al. JAAD Case Rep. .
No abstract available

Keywords: Tyk2; autoimmune disease; cutaneous lupus erythematosus; deuravacitinib; treatment.

PubMed Disclaimer

Conflict of interest statement

Dr Merola is a consultant and/or investigator for Amgen, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly, Incyte, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer, and Leo Pharma. Author Zhang and Dr Gaffney have no conflicts of interest to declare.

Figures

Fig 1
Fig 1
A 51-year-old male pretreatment and posttreatment of tumid lupus erythematosus with deucravacitinib after 4 months. A, Right anterior lower extremity, B, left anterior lower extremity, and C, right upper extremity with violaceous, indurated plaques before addition of deucravacitinib therapy. D, Right anterior lower extremity, E, left anterior lower extremity, and F, right upper extremity 3 months after initiation of deucravacitinib therapy, with residual improved violaceous changes and minimal skin thickening at sites of previous plaques.
See this image and copyright information in PMC

References

    1. Petty A.J., Floyd L., Henderson C., Nicholas M.W. Cutaneous lupus erythematosus: progress and challenges. Curr Allergy Asthma Rep. 2020;20(5):12. doi: 10.1007/s11882-020-00906-8. - DOI - PMC - PubMed
    1. Morand E., Pike M., Merrill J.T., et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023;75(2):242–252. doi: 10.1002/art.42391. - DOI - PMC - PubMed

Publication types

LinkOut - more resources